## H Arzu YaÅŸr

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2655510/publications.pdf

Version: 2024-02-01

1684188 1588992 64 12 5 8 citations h-index g-index papers 12 12 12 70 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	The relationship between prognostic nutritional index and treatment response in patients with metastatic renal cell cancer. Journal of Oncology Pharmacy Practice, 2020, 26, 1110-1116.	0.9	19
2	Prognostic factors for survival in patients with mucosal and ocular melanoma treated with ipilimumab: Turkish Oncology Group study. Journal of Oncology Pharmacy Practice, 2020, 26, 267-272.	0.9	8
3	Prognostic factors for survival in patients with metastatic malign melanoma treated with ipilimumab: Turkish Oncology Group study. Journal of Oncology Pharmacy Practice, 2019, 25, 1658-1664.	0.9	7
4	Sweet's syndrome under ipilimumab therapy and a brief comparison of the cases in literature. Journal of Oncology Pharmacy Practice, 2020, 26, 1762-1764.	0.9	7
5	Neutrophil–lymphocyte ratio as a prognostic factor for survival in patients with advanced renal cell carcinoma (Turkish Oncology Group Study). Journal of Oncology Pharmacy Practice, 2020, 26, 1583-1589.	0.9	6
6	Kaposi sarcoma associated with rituximab-based cytotoxic therapy. Journal of Oncology Pharmacy Practice, 2020, 26, 220-223.	0.9	5
7	A systematic review: Role of systemic therapy on treatment and prevention of brain metastasis in renal cell carcinoma. Journal of Oncology Pharmacy Practice, 2020, 26, 972-981.	0.9	5
8	Worse patient–physician relationship is associated with more fear of cancer recurrence (Deimos) Tj ETQq0 0 C European Journal of Cancer Care, 2020, 29, e13296.	rgBT /Ov 1.5	erlock 10 Tf 5 3
9	Central nervous system involvement in patients with acute myeloid leukemia. Turkish Journal of Medical Sciences, 2021, 51, 2351-2356.	0.9	2
10	Targeted Agents and Resistance Mechanism in Renal Cell Cancer. Üroonkoloji Bülteni, 2019, 18, 73-79.	0.1	1
11	Clinicopathological associations of acquired erythroblastopenia. International Journal of Clinical and Experimental Medicine, 2015, 8, 22515-9.	1.3	1
12	Re: Combination of radiotherapy and immunotherapy? Do timing and dose matter?. Journal of Oncology Pharmacy Practice, 2019, 25, 2062-2063.	0.9	0